Table 2.
Comparison of the sociodemographic and metabolic parameters between men and women according to the BMI categories in patients with type 2 diabetes
| Total patients (n = 4,648) |
BMI <30 (n = 1,907) |
BMI 30 (n = 2,741) |
|||||
|---|---|---|---|---|---|---|---|
| female (n = 820; 43%) |
male (n = 1,087; 57%) |
p | female (n = 1,911; 69.7%) |
male (n = 830; 30.3%) |
p | ||
| Age, years | 58.48 ± 10.45 | 59.73 ± 11.11 | 59.12 ± 10.79 | 0.231 | 57.80 ± 10.08 | 57.98 ± 10.05 | 0.675 |
| HbA1c, % | 7.73 ± 1.74 | 7.59 ± 1.79 | 7.62 ± 1.71 | 0.660 | 7.83 ± 1.76 | 7.78 ± 1.65 | 0.547 |
| DM duration, years | 10.84 ± 7.53 | 11.24 ± 7.88 | 10.47 ± 7.75 | 0.035 | 11.10 ± 7.33 | 10.33 ± 7.30 | 0.012 |
| Exercise | 896 (19.6) | 177 (21.8) | 285 (26.7) | 0.015 | 269 (14.3) | 165 (20.3) | <0.001 |
| Smoking | 588 (12.7) | 89 (10.9) | 205 (18.9) | <0.001 | 164 (8.6) | 130 (15.7) | <0.001 |
| Higher education | 1,765 (38.5) | 258 (32.0) | 696 (64.4) | <0.001 | 400 (21.2) | 411 (50.4) | <0.001 |
| LDL-C, mg/dL | 113.92 ± 36.17 | 122.47 ± 39.43 | 108.86 ± 33.36 | <0.001 | 116.21 ± 36.02 | 106.91 ± 34.43 | <0.001 |
| HDL-C, mg/dL | 46.58 ± 12.93 | 52.59 ± 14.73 | 43.54 ± 11.92 | <0.001 | 48.28 ± 12.22 | 40.71 ± 10.21 | <0.001 |
| TG, mg/dL | 181.75 ± 128.47 | 169.73 ± 135.06 | 169.33 ± 126.75 | 0.948 | 185.67 ± 120.23 | 200.92 ± 139.38 | 0.005 |
| eGFR, mL/min | 87.45 ± 30.05 | 86.98 ± 23.60 | 86.61 ± 40.41 | 0.842 | 88.64 ± 27.94 | 86.19 ± 23.50 | 0.054 |
| Microvascular complications | 2,209 (47.5) | 356 (43.4) | 459 (42.2) | 0.604 | 978 (51.2) | 416 (50.1) | 0.611 |
| Macrovascular complications | 1,123 (24.2) | 149 (18.2) | 314 (28.9) | <0.001 | 394 (20.6) | 266 (32.0) | <0.001 |
| Home ABP <135/85 mm Hg | 3,219 (69.8) | 616 (75.5) | 808 (75.0) | 0.789 | 1,253 (66.2) | 542 (65.8) | 0.848 |
| LDL-C levels <100 mg/dL | 1,644 (37.3 | 234 (30.2) | 443 (42.4) | <0.001 | 618 (34.3) | 349 (44.6) | <0.001 |
| HbA1c levels <7% | 1,820 (40.1) | 357 (44.9) | 466 (43.8) | 0.634 | 703 (37.7) | 294 (36.2) | 0.451 |
| Triple target | 472 (10.4 | 71 (8.9) | 157 (14.8) | <0.001 | 154 (8.2) | 90 (11.1) | 0.019 |
| Insulin treatment | 2,147 (46.2) | 323 (39.4) | 480 (44.2) | 0.037 | 922 (48.2) | 422 (50.8) | 0.212 |
| OAD treatment | 4,126 (88.8) | 720 (88.7) | 944 (86.8) | 0.234 | 1,736 (90.8) | 719 (86.6) | 0.001 |
| OADs, n | 1.51 ± 0.92 | 1.47 ± 0.89 | 1.52 ± 0.96 | 0.305 | 1.49 ± 0.86 | 1.56 ± 0.99 | 0.064 |
| Anti-HT treatments | 2,754 (59.3) | 468 (57.1) | 543 (50.0) | 0.002 | 1,234 (64.6) | 509 (61.3) | 0.104 |
| Anti-HT drug count | 1.74 ± 0.85 | 1.64 ± 0.77 | 1.64 ± 0.83 | 0.921 | 1.77 ± 0.85 | 1.84 ± 0.91 | 0.129 |
| Statin treatment | 1,836 (39.5) | 306 (37.3) | 418 (38.5) | 0.612 | 759 (39.7) | 353 (42.5) | 0.168 |
Data are presented as n (%) or mean ± SD. HbA1c, glycated hemoglobin; DM, diabetes mellitus; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglycerides; eGFR, estimated glomerular filtration rate; ABP, arterial blood pressure; OAD, oral antidiabetic drugs; HT, hypertension.